Real-world data confirm that Rezūm therapy, a minimally invasive procedure that uses water vapor to ablate prostate tissue, is safe and effective for treating benign prostatic hyperplasia (BPH) over a wide range of prostate volumes, including glands 80 mL or larger, according to a presentation at the 2022 American Urological Association annual meeting in New Orleans, Louisiana, and published online ahead of print in Urology.
The findings are from a large multicenter prospective registry study of 229 patients with a mean age of 67.3 years treated with the procedure. The group included 83 patients with prostate volumes of 80 mL or larger. The mean prostate volume was 71.5 mL (range 20-160 mL).
Patients received a mean of 11 injections (range 4-28). The mean duration of the procedure was 4.8 minutes (range 1.5-14). The mean duration of post-procedure catheterization was 9.8 days.
Continue Reading
Patients’ International Prostate Symptom Score (IPSS) decreased from 22 at baseline to 15.8, 10.3, and 9.3 at 1, 3, and 12 months, respectively, lead investigator Dean Elterman, MD, of University Health Network, University of Toronto, Canada, reported. The IPSS quality of life (QoL) score improved from a baseline of 4.4 to 2.2 and 1.5 at 3 and 12 months, respectively. The peak flow rate (Qmax) increased from 8.7 mL/s at baseline to 13.9 mL/s at 3 months. Post-void residual volume values improved by 63%, 51%, and 61% at 1, 3, and 12 months.
Results showed no significant changes in International Index of Erectile Function (IIEF)-15 score and Male Sexual Health Questionnaire (MSHQ) score for function or bother.
The investigators conducted a subgroup analysis of the patients with glands 80 mL or larger (mean 104.6 mL). The mean duration of the procedure was 5.9 minutes and mean duration of post-procedure catheterization was 11.8 days. The IPSS declined significantly from a baseline score of 20.9 to 15.8, 9.0, and 8.4 at 1, 3, and 12 months, respectively. IPSS QoL score improved from a baseline of 4.2 to 1.8 and 1.4 at 3 and 12 months, respectively. Qmax increased significantly from 9.2 mL/s at baseline to 14.3 mL/s at 3 months. The investigators observed no significant change in IIEF-15 scores, MSHQ function, or bother.
No Clavien-Dindo events of grade 3 or higher occurred, according to the investigators.
Disclosure: The investigators report being consultants to Boston Scientific, which markets Rezūm.
References
Elterman D, Bhojani N, Chughtai B, Zorn KC. Large, multi-center, prospective registry of Rezūm water vapor therapy benign prostatic enlargement. Presented at AUA2022, May 13-16, 2022, New Orleans, Louisiana. Poster MP01-11.
Elterman D, Bhojani N, Chughtai B, Zorn KC. Large, multi-center, prospective registry of Rezūm water vapor therapy benign prostatic enlargement. Urology. Published online February 17, 2022. doi:10.1016/j.urology.2022.02.001
